On June 3, 2020, a proposed class action was commenced against over 50 generic drug manufacturers (see Statement of Claim here). The claim alleges that the generic drug manufacturers violated the Competition Act by conspiring to allocate the market, fix prices and maintain the supply of generic drugs from 2012 to present, and claims damages or compensation of $2.75 billion. The action is brought on behalf of class members who purchased generic drugs in the private sector, either through private drug plans or paying cash. The claim alleges that the defendants conspired to allocate the market for generic drugs by agreeing whether to sell certain drugs, and by fixing the market shares and prices of drugs. The claim references an ongoing investigation in the United States into price fixing, bid rigging and market allocation in the generic pharmaceutical industry, in which certain manufacturers have entered guilty pleas (see press release here in respect of Apotex Corp.).
Related Publications & Articles
-
Final report from advisory panel on potential pan-Canadian formulary is released
As previously reported, on January 11, the Canadian Agency for Drugs and Technologies in Health (CADTH) posted a discussion paper regarding the proposed framework for a potential pan-Cana...Read More -
Janssen succeeds on infringement against Apotex in macitentan combination patent case
In a public decision dated July 6, 2022 in an action under the Patented Medicines (Notice of Compliance) Regulations, Justice Pallotta of the Federal Court found that Apotex would infringe Janssen’s p...Read More -
2022 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2022, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More